FDA, WADA, DEA and gray-market status — date-stamped and primary-sourced.
Legal & Regulatory tracks the fast-moving status of peptides: FDA approval versus compounding eligibility, the 2023-2026 Category-2 timeline, WADA anti-doping status, DEA scheduling, the research-chemical gray market, and US-versus-international differences. Regulatory facts change constantly, so every statement here is date-stamped and sourced to a primary FDA, WADA or DEA document.
"Legal" is not one question but five — FDA approval, compounding eligibility, DEA scheduling, WADA sport status, and state telehealth law. A date-stamped 2026 explainer of where peptides actually stand.
It depends entirely on the peptide. A few (semaglutide, tirzepatide, PT-141) are FDA-approved drugs available by prescription. Many others are not approved and are sold as "research chemicals not for human use," which exist in a legal gray zone — possession and sale for research may be tolerated, but human use is not authorized and quality is unregulated. Several peptides are also prohibited in sport. We date-stamp every legal statement because this landscape changes frequently.
In September 2023 the FDA moved roughly 19 compounded peptides — including BPC-157 and TB-500 — into 503A Category 2 ("may present significant safety risks"), effectively prohibiting their use as bulk substances in compounding. On April 15, 2026 the FDA removed 11 peptides from Category 2 — but because the nominations were withdrawn, not because the substances were found safe. That leaves them in a gray zone: no longer prohibited, but not authorized. An advisory-committee (PCAC) review is scheduled for July 2026. Removal from Category 2 does not equal approval to compound.
No — this is a critical and widely misunderstood point. To be lawfully used in 503A compounding, a bulk substance must comply with a USP/NF monograph, be a component of an FDA-approved drug, or appear on the 503A Bulks List (Category 1). The April 2026 removals took peptides off the prohibited Category 2 list but did not place them on the permitted Category 1 list. They remain unauthorized for compounding and are still sold as research chemicals not for human use.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.